Murphy Canyon Acquisition Corp. Warrant (CDTTW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Murphy Canyon Acquisition Corp. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 534,362 | $5,663.86 | $10,687.24 | $5,023.38 | 88.69% |
| OC Olivia Cooper Decagon Asset Management LLP | 400,000 | $3,680 | $8,000 | $4,320 | 117.39% |
Murphy Canyon Acquisition Corp. Warrant (CDTTW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Murphy Canyon Acquisition Corp. Warrant ever had a stock split?
Murphy Canyon Acquisition Corp. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Andrew Regan CEO | NASDAQ (CM) Exchange | 20678X114 CUSIP |
| US Country | 6 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Conduit Pharmaceuticals Inc. is a pioneering clinical-stage specialty biopharmaceutical company focused on developing innovative pharmaceutical products to address unmet medical needs in the realms of autoimmune diseases and idiopathic male infertility. Founded in 2019 and headquartered in San Diego, California, the company emerges as a significant player in the biopharmaceutical landscape. As a subsidiary of Corvus Capital Limited, Conduit Pharmaceuticals Limited leverages cutting-edge science and research to push the boundaries of medical treatment and offers hope to patients suffering from conditions that currently lack effective therapies.
Products and Services
- AZD1656
- AZD5904
This compound has successfully completed Phase I trials, marking its potential as a versatile treatment option for several autoimmune conditions and medical scenarios. Specifically, AZD1656 is being investigated for its efficacy in treating type 2 diabetes, renal transplant rejection prevention, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor. Each of these areas represents a significant unmet medical need, with AZD1656 standing out as a beacon of hope for diverse patient populations.
AZD5904 has completed Phase I clinical trials, focusing on the treatment of idiopathic male infertility. This condition, often overlooked in the broader scope of reproductive health, signifies a crucial area of medical research and innovation. By targeting idiopathic male infertility, AZD5904 showcases Conduit Pharmaceuticals Inc.'s commitment to addressing complex health challenges through advanced pharmaceutical development and clinical research.
